{"analyses":[{"ciLowerLimit":"0.51","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.71","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.60","statisticalMethod":"Stratified log rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.5","upperLimit":"7.4","value":"7.2"},{"groupId":"OG001","lowerLimit":"2.8","upperLimit":"3.7","value":"3.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"353"}],"units":"Participants"}],"description":"Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause, in the global cohort.\n\nParticipants who discontinue treatment prior to progression should continue to be scanned until progression.\n\nProgression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s).","dispersionType":"95% Confidence Interval","groups":[{"description":"Capivasertib: 400 mg twice daily (2 tablets of 200 mg taken orally twice daily; total daily dose 800 mg) given on an intermittent weekly dosing schedule (4 days on/3 days off).\n\nFulvestrant: 500 mg (2 intramuscular injections of 250 mg/5 mL solution) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter.","id":"OG000","title":"Capivasertib + Fulvestrant (Global + China Cohort)"},{"description":"Placebo: Placebo tablets matching capivasertib. 400 mg twice daily (2 tablets of 200 mg taken orally twice daily; total daily dose 800 mg) given on an intermittent weekly dosing schedule (4 days on/3 days off).\n\nFulvestrant: 500 mg (2 intramuscular injections of 250 mg/5 mL solution) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter.","id":"OG001","title":"Placebo + Fulvestrant (Global + China Cohort)"}],"paramType":"MEDIAN","populationDescription":"Overall population in the global cohort","reportingStatus":"POSTED","timeFrame":"Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.","title":"Progression Free Survival: Overall Population (Months) in the Global Cohort","type":"PRIMARY","unitOfMeasure":"Months"}